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Introduction {#j_raon-2019-0053_s_001}
============

The 8th edition of tumour-node-metastases (TNM) staging system for lung cancer came into practice in January 2018 and replaced 7^th^ edition from 2007.[@j_raon-2019-0053_ref_001], [@j_raon-2019-0053_ref_002], [@j_raon-2019-0053_ref_003] TNM classification is a coding system for the anatomic extent of the disease. By its definition it does not include tumour markers, genetic signatures, comorbidities etc., which are all known to influence the survival. Nevertheless, the authors of new TNM proposal pointed out improvement in survival curves as one of major reasons for the change of classification. Several new diagnostic, imaging and treatment developments were introduced during the period in which patients were included, from 1990 to 2000. New imaging techniques such as PET/CT and MRI influence the stage migration, while the new treatment with targeted agents and immunotherapy influences the survival curves.[@j_raon-2019-0053_ref_004], [@j_raon-2019-0053_ref_005], [@j_raon-2019-0053_ref_006], [@j_raon-2019-0053_ref_007], [@j_raon-2019-0053_ref_008], [@j_raon-2019-0053_ref_009] The majority of new improvements and developments in the last 15 years were implemented for metastatic patients and therefore affected mostly M descriptor. With new classification there are no changes of M1a category, while there is further sub-classification of M1b category into M1b (single distant metastatic lesion in single organ) and M1c (multiple metastases in one organ or in multiple distant metastatic sites).[@j_raon-2019-0053_ref_010] There is growing evidence showing that information on molecular tumour status significantly affects treatment response and survival.[@j_raon-2019-0053_ref_011], [@j_raon-2019-0053_ref_012], [@j_raon-2019-0053_ref_013], [@j_raon-2019-0053_ref_014], [@j_raon-2019-0053_ref_015], [@j_raon-2019-0053_ref_016] This report points on impact of epidermal growth factor receptor (EGFR) mutation on survival in view of new TNM classification system.

Patients and methods {#j_raon-2019-0053_s_002}
====================

Medical records of 479 consecutive metastatic non-small cell lung cancer (NSCLC) patients, treated between 2009 and 2011, all tested for EGFR mutations were retrospectively reviewed. They were categorized into sub-groups according to new M descriptors. For 355 out of 479 patients, among them 89 (25.1%) with EGFR mutations (EGFR-m), there was sufficient information in medical records that allowed appropriate new categorisation according to new TNM classification. Median overall survival was calculated from the date of diagnosis to the death or last follow up and estimated using Kaplan-Meier method.[@j_raon-2019-0053_ref_017] The association between the EGFR mutation status and the clinico-pathological characteristics of patients were tested using the Mann-Whitney U (MW-U) or the Kruskal Wallis H (KW-H) test. Survival and prognosis was assessed using Cox proportional hazard regression analysis. All p values reported were based on the two-sided hypothesis. Data was calculated using SPSS v.20 statistical package.

This analysis is part of a retrospective study approved by Institutional Review Board Committee and National Ethics Committee (No.143/1/2011).

Results {#j_raon-2019-0053_s_003}
=======

Totally, 355 patients were included in final analysis, of those 89 (25.1%) were EGFR-m positive. Median age of all patients was 64.4 years (range 25-88). Majority were male, current or former smokers and had adenocarcinoma. Data on basic patients' characteristics are listed in [Table 1](#j_raon-2019-0053_tab_001){ref-type="table"}.

###### 

Baseline characteristics of patients by EGFR mutation status

  Characteristics                  All     EGFR-wt            EGFR-m          
  -------------------------------- ------- --------- -------- -------- ------ ----------
  **All patients**                 355     266       75       89       25     
  **Age (years)**                                                             
  median                           64.4    63.5      65.6     65.6            0.98
  range                            25-88   25--87    25--87   36--88          
  **Gender**                                                                  
  female                           165     107       40.2     58       65.2   \< 0.001
  male                             190     159       59.8     31       34.8   
  **Smoking status**                                                          \< 0.001
  current                          142     132       49.6     10       11.2   
  former                           101     81        30.5     20       22.5   
  never                            95      40        15.0     55       61.8   
  unknown                          17      13        4.9      4        4.5    
  **Histology**                                                               
  adenocarcinoma                   309     232       87.2     77       86.2   0.86
  non-small cell lungcancer, NOS   46      34        12.8     12       13.5   
  **Metastatic sites\***                                                      
  Brain                            86      61        22.9     25       28.1   0.33
  Bone                             151     104       39.1     47       52.8   0.02
  Lung                             157     106       39.8     51       57.3   0.01
  Pleura                           115     83        31.2     32       36.0   0.48
  Liver                            55      40        15.0     15       16.9   0.68
  Adrenal gland                    49      43        16.2     6        6.7    0.02
  Distant lymph nodes              55      46        17.3     9        10.1   0.10
  Other sites                      40      34        12.8     6        6.7    0.11

\* Sum of all metastasis is more than 355 as some patients had multiple metastases; EGFR-m = patients harboured EGFR mutations; EGFR-wt = EGFR wild type patients

The distribution of metastases according to EGFR mutation status differed between the two groups, with metastases to bones and lung being more frequent in EGFR-m patients compared to EGFR wild type (EGFR-wt) patients, while metastases to adrenal gland were less frequent in EGFR-m patients as compared to EGFR-wt patients.

Most of the patients with EGFR-m tumors were primary treated with EGFR tyrosine kinase inhibitors (TKIs) (71 cases, 79%). Chemotherapy (ChT) was applied to 10 patients as first-line systemic treatment while after progression to ChT treatment with TKI was the most common. Eight patients with EGFR-m tumors did not receive any form of systemic treatment. The reason could not be clearly established from the medical records.

For patients with EGFR-wt tumors, platinum based chemotherapy was the most common form of systemic treatment (150/266 cases, 56.4%). In 29 patients, TKIs were used for maintenance treatment. In the group of EGFR-wt patients, no systemic treatment was given to 87 patients (33%) due to bad performance status and comorbidities, while palliative irradiation of symptomatic sites was used in some patients in addition to best supportive care.

We compared mOS of patients with and without systemic therapy according to EGFR mutation status. As expected, EGFR-m patients treated with TKI had longer survival than EGFR-m patients on symptomatic treatment only (21.3 *vs*. 3.3 month), though the number of non-treated patients was too low to draw any firm conclusions. Similarly, EGFR-wt patients who received chemotherapy had longer mOS than those without treatment (12.4 *vs*. 2.8 months). EGFR-m patients receiving best supportive care only, showed trend to better survival compared to EGFR-wt on best supportive care, but additional analysis was futile due to small number of cases in subcategories.

Patients were first categorized according to 7^th^ TNM classification and according to their EGFR mutation status. Secondly, patients with 7^th^ M1b category were grouped to those who had single metastatic site/organ and those with multiple metastases, presented in [Table 2](#j_raon-2019-0053_tab_002){ref-type="table"}.

###### 

Overall survival of EGFR-m compared to EGFR-wt patients based on the M1b status in 7^th^ TNM classification for single and multiple metastatic sites/organs

  Metastatic sites (old M1b only)   all   EGFR-m   EGFR-wt   p            
  --------------------------------- ----- -------- --------- ----- ------ ----------
  Single organ                      72    14       32.5      58    11.5   \< 0.001
  Multiple organs                   205   58       17.4      147   6.1    \< 0.001
  All                               277   77       20.5      205   7.8    \< 0.001

EGFR-m = patients harboured EGFR mutations; EGFR-wt = EGFR wild type patients

Finally, we joined cases with multiple metastatic sites and those with multiple metastases in one organ to form new M1c, incorporating also EGFR mutation status following the process shown in [Figure 1](#j_raon-2019-0053_fig_001){ref-type="fig"}.

![Diagram of division: From 7^th^ to 8^th^ TNM classification with incorporation of EGFR mutation status.\
EGFR-m = patients harboured EGFR mutations; EGFR-wt = EGFR wild type patients](raon-53-453-g001){#j_raon-2019-0053_fig_001}

Survival results show that mOS was better for all metastatic EGFR-m patients compared to metastatic EGFR-wt patients ( 20.6 *vs*. 8.3 months, p \< 0.001). Detailed mOS for new versus old M descriptor is shown in [Table 3](#j_raon-2019-0053_tab_003){ref-type="table"}.

###### 

M descriptors for 7^th^ and 8^th^ TNM classification according to EGFR mutation status and their median overall survival (mOS) in months

                                 7^th^ TNM classification                                           
  ------------------------------ -------------------------- ------------ ------ ----- ------------- ----------
  M1a                            78                         17           22.4   61    10.7          0.025
  M1b                            252                        72           18.8   205   7.9           \< 0.001
  All                            355                        89           20.6   266   8.3           \< 0.001
                                                                                                    
  **8^th^ TNM classification**                              **EGFR-m**                **EGFR-wt**   
                                                                                                    
  M1a                            78                         17           22.4   61    10.7          0.025
  M1b                            37                         5            39.2   32    14.4          0.082
  M1c                            240                        67           18.8   173   6.6           \< 0.001
  All                            355                        89           20.6   266   8.3           \< 0.001

EGFR-m = patients harboured EGFR mutations; EGFR-wt = EGFR wild type patients

Patients with metastases to single organ only had better survival than those who had metastases in multiple organs, irrespective of the presence of EGFR mutations (14.4 and 7.9 months, p = 0.006). Significantly better overall survival of EGFR-m patients compared to EGFR-wt patients was seen in group of patients with single organ metastases only as well as in group with metastases in multiple organs (p \< 0.001).

Survival curves of different new M categories (TNM 8^th^ edition) according to EGFR mutation status are presented in [Figure 2](#j_raon-2019-0053_fig_002){ref-type="fig"}.

![Survival curves of different M categories according to EGFR mutation status based on 8^th^ TNM classification.\
EGFR-m = patients harboured EGFR mutations; EGFR-wt = EGFR wild type patients](raon-53-453-g002){#j_raon-2019-0053_fig_002}

Distribution of metastatic spread to different organs with regard to EGFR mutation status was also analysed. In EGFR-m patients multiple metastases were observed in all organs, the only exception being the adrenal gland where there was only one case with single metastases. On the contrary, EGFR-wt patients had more frequently either one or multiple metastases in single organ. Site specific mOS with regard to EGFR mutation status is shown in [Table 4](#j_raon-2019-0053_tab_004){ref-type="table"}. EGFR-m patients with metastases to brain, bone, lung and pleura have significantly better survival than EGFR-wt patients, while no statistical difference was noted for other metastatic sites.

###### 

Site specific median overall survival (mOS) according to EGFR mutation status

  Metastatic site       Patients          mOS          
  --------------------- ---------- ------ ------ ----- --------------
  Brain                 86         8.1    14.9   7.1   **0.003**
  Bone                  151        9.4    21.3   6.7   **\< 0.001**
  Lung                  157        11.9   20.2   8.3   **0.002**
  Pleura                115        8.8    20.6   6.5   **\< 0.001**
  Liver                 55         5.6    10.4   5.5   0.245
  Adrenal gland         49         5.2    4.9    5.5   0.595
  Distant lymph nodes   55         6.2    13.0   5.5   0.237
  Other sites           40         8.9    14.9   8.4   0.156

EGFR-m = patients harboured EGFR mutations; EGFR-wt = EGFR wild type patients

Discussion {#j_raon-2019-0053_s_004}
==========

Our retrospective review analyzed metastatic non-small cell lung cancer patients with objective to categorize them according to new M descriptor incorporating also the data on EGFR mutation status. In the proposal of new M descriptor 1059 metastatic cases were included into detailed survival analysis.[@j_raon-2019-0053_ref_010] Since the patients were diagnosed between 1999 and 2012, not all could have had EGFR mutation testing, as this was not a routine procedure before the year 2004.[@j_raon-2019-0053_ref_018] Their main purpose was analysis of expected change in survival curves due to stage migration, incorporating new diagnostic procedures (PET/CT) and new treatment options with local approaches, especially irradiation of oligometastatic sites as well as improvement in systemic treatment, mainly molecular targeted agents.[@j_raon-2019-0053_ref_019] In our single institution analysis 355 patients were included, which represent one third (35.5%) of cases published in a paper that is proposing and justifying the classification changes.

In further detailed analysis of distribution pattern of metastatic spread according to EGFR mutation status, we first divided patients by organ/site they metastasized to rather than number of metastasis in a single organ. As shown in this analysis and known also from clinical practice and previous studies, patients with single metastatic site (organ) have better prognosis than those with multiple metastatic sites.[@j_raon-2019-0053_ref_020] Patients with low number of metastatic sites are known to have oligometastatic disease, though the definitions differ and current guidelines propose modified treatment.[@j_raon-2019-0053_ref_021], [@j_raon-2019-0053_ref_022], [@j_raon-2019-0053_ref_023] The new M descriptor does not define oligometastatic disease in a way that would help clinicians make decision about the treatment. For example, treatment and prognosis of patients with one metastasis in the brain (M1b) might be the same as of three small metastases (M1c).[@j_raon-2019-0053_ref_024] Similarly, treatment of one metastasis in the liver (M1b) will probably be the same as for multiple metastases (M1c). One special situation is metastasis to the adrenal gland. Therapeutic options for metastasis to the adrenal gland as a single metastatic site are local treatments, either irradiation or operation.[@j_raon-2019-0053_ref_025], [@j_raon-2019-0053_ref_026] No cases with more than one metastasis in a single adrenal gland were observed in the current analysis. Patients with metastases in the adrenal gland, which are often affected on both sides, have bad prognosis and survival. According to our analysis, patients with metastases to adrenal gland have the worst survival regardless of EGFR-m status. In addition, other researchers noticed that patients with adrenal gland metastasis showed impaired survival.[@j_raon-2019-0053_ref_010] However, based on their data they concluded that the site of metastasis is not prognostic for single or multiple lesions within the single organ. It is questionable whether one or more metastases in a single organ really influence survival. On the contrary, current analysis suggests that the number of metastatic sites might be more important prognostic factor than number of metastatic lesions in one organ.

Even though large number of patients was included in our series, only 5 patients with EGFR mutations were sub-classified into M1b category. It seems that once EGFR-m tumors metastasize they do it in aggressive and widespread way. For the first time we have shown that not only have EGFR-m patients better mOS than EGFR-wt patients but also better mOS in each sub-category of M descriptor. This analysis showed that in spite of widespread metastatic disease (M1c) and high tumor burden, EGFR-m patients treated with TKI had longer mOS (18.8 months) than EGFR-wt patients with only one metastasis (M1b) (14.4 months). Likely, EGFR-m status has greater impact on survival curves than different sub-categories of M descriptor.

We are aware of the need for simple and predictable system for classification in prognostic groups of patients with lung cancer. However, according to our survival data it seems that TNM classification is inadequate for relevant prediction of survival, because in some cases, as we show for EGFR mutations, molecular feature is more important than anatomical distribution of malignant disease. Maybe we should consider adding the new descriptor to TNM classification that labels molecular feature of tumor. Recently, investigators from University of California published an article on how integration of molecular prognostic classifier into TNM system might improve identification of high-risk patients and predict survival in non-metastatic NSCLC. They used 11 cancer-related target genes; however, they did not include current biomarkers such as EGFR, KRAS ALK, which was recognized as an important drawback of their study.[@j_raon-2019-0053_ref_027]

There are some important limitations to the current analysis. It was not possible to find reliable metastatic information for about 25% of cases in our database, which could not be included in the analysis. It should be recognized that due to small number of series those might be the cases that could influence the results and represent the potential bias. There were also more patients with symptomatic treatment among EGFR-wt patients than EGFR-m patients, reflecting real clinical situation. However, this is not surprising as majority of EGFR-m patients are nonsmokers and have less co-morbidities. Also, in contrast to EGFR-wt patients who can receive chemotherapy only in good performance status (PS) 0-2, EGFR-m patients may also receive TKI in poor PS ([@j_raon-2019-0053_ref_003], [@j_raon-2019-0053_ref_004]). Due to retrospective nature of the study not all metastatic sites rather symptomatic ones were diagnosed and collected in routine clinical practice.

Conclusions {#j_raon-2019-0053_s_005}
===========

Number of metastatic sites might be more important predictive survival factor than number of metastatic lesions in single organ, though both fall into M1c category. Incorporation of EGFR mutation status seem to predict survival more reliably than the number of metastasis or number of metastatic sites in NSCLC. Our results indicate that further analysis with incorporation of information on also other molecular status is warranted to further improve differentiation of survival curves in the future.

[^1]: Data from this research have been partly presented as poster at 17^th^ World Conference on Lung Cancer 2016 in Vienna.
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